b'Closing Notes & TimelineJohns Hopkins as a Co-Leader for ClinicalDr. Zhijian James Chen reports that cGASsuccessful competition for a $1.1 million awardDrs. Kenneth Chen, Amatruda, and Mendell Research. He is the inaugural recipient of theis required for the antitumor effect of immunefrom the Cancer Prevention and Researchreport molecular insights into the development Eugene P. Frenkel Endowed Scholar Award.checkpoint inhibitors. (Wang et al., PNAS, 2017) Institute of Texas (PI, Brugarolas).of Wilms tumors by DROSHA and DICER1 Dr. Margulis reports on a 15-year experienceDrs. Bowman and Brugarolas report that aDr. DeBerardinis is awarded an NCImutations. (Chen et al., Genes Dev, 2018; with surgery for tumor thrombi. (Gayed et al.,primary lung cancer may be identified in moreOutstanding Investigator Award.Hunter et al., Genes Dev, 2018) BMC Urol, 2016)than 5 percent of patients with metastaticPatient Advocate Merlinda Chelette, withDr. Cole is recruited to UT Southwestern as Dallas Mayor Mike Rawlings andkidney cancer. (Bowman et al., Clin GenitourinDirector of the University Hospital Simmons Dr. Brugarolas at inauguration event. In a team effort led by Dr. Brugarolas, the pro- Cancer, 2017) support from the Kidney Cancer Coalition,Cancer Clinic at the UT Southwestern Medical gram becomes the second program in the U.S.organizes a golf tournament fundraiser at theCenter in Richardson/Plano, Texas.to receive a prestigious $11 million SpecializedPatient Advocates supported by the KidneyCowboys Golf Club, raising over $25,000.Dallas Morning News journalist and reporter 2014 Program of Research Excellence (SPORE)Cancer Coalition organize first fundraising eventRobert Wilonsky discusses his battle withDrs. Wang and Brugarolas report the first empir-award from the National Cancer Institute. at Dallas Country Club, raising over $100,000. The Kidney Cancer Program hosts the firstkidney cancer at the KCP Annual Event. ical approach using tumorgrafts to dissect the Drs. Rakheja, Mendell, and Amatruda reportretreat for trainees and awards prizes to the identification of mutations in DROSHADr. Hannan reports UT Southwestern experi- Dr. Pirasteh and medical student Daniel Li fortumor microenvironment. (Wang et al., Cancer and DICER1 in Wilms tumors. (Rakheja et al.,ence with SBRT for metastatic renal cancer,their research. The program and SPORE award $25,000 inDiscov, 2018) Nat Commun, 2014) the largest worldwide. (Wang et al., Int J RadiatDr. Brugarolas is appointed inaugural chair ofpilot grants to Drs. Ariizumi, Diaz de Leon,Dr. Madhuranthakam develops a whole-body Dr. Brugarolas reports the first geneticallyOncol Biol Phys, 2017) the programmatic panel of the newly estab- Drake, Grishin, Huen, Jiang, Koh, Malladi, Mani,MRI protocol that improves the detection of engineered mouse model reproducing thePatient Advocate Tony Towler is nominatedlished Congressionally directed Kidney CancerRethorst, and Wang.bone metastases by 30 percent. (Wang et al., mutations of human ccRCC. (Wang et al.,Volunteer of the Year by the Dallas-Fort WorthResearch Program.Dr. Hammers, one of three co-principal investi- Magn Reson Med, 2018)PNAS, 2014) Hospital Council. Drs. Pedrosa and Cadeddu report a new multi- gators, reports the results of CheckMate-214,Dr. Timmerman receives ASTRO Fellow 2015 NCI SPORE winning team. Dr. Hammers publishes a landmark clinicalparametric MRI approach with high sensitivitya phase 3 clinical trial of ipilimumab/nivolumab,designation. trial (NCT01472081) showing a doubling ofand specificity for the detection of ccRCC,heralding the most important FDA approval forDrs. Courtney and DeBerardinis report the results In collaboration with Genentech,response rates with combination immunother- which may reduce the need for biopsies.kidney cancer. (Motzer et al., N Engl J Med,of the first radioactively labeled nutrient studies in Drs. Kapur and Brugarolas report the firstDrs. Brugarolas, Kapur, Hammers, and Hannanapy with ipilimumab plus nivolumab. (Hammers(Canvasser et al., J Urol, 2017) 2018) humans to understand how kidney cancer grows. integrated analysis of non-clear cell renal car- become members of the Renal Task Force ofet al., J Clin Oncol, 2017) The American Urological Association selects for(Courtney et al., Cell Metab, 2018) cinoma subtypes. (Durinck et al., Nat Genet,the Genitourinary Cancer Steering CommitteeThe Urology Department begins providing carepresentation at the Plenary Session of its Annual 2015) of the National Cancer Institute. The program and SPORE award pilot grantsat John Peter Smith Hospital, a 573-bed countyMeeting an abstract from UT SouthwesternsDr. Zhijian James Chen reports on the role of Dr. Cadeddu reports the first experience withThe Kidney Cancer Program and SPORE awardranging from $25,000 to $40,000 to hospital in Fort Worth, ensuring that Tarrantgroundbreaking clinical trial (NCT02473536)NLRP3 in activating the inflammasome during irreversible electroporation for percutaneouspilot grants ranging from $25,000 to $40,000 toDrs. Banaszynski, Cadeddu, Chuo Chen,County residents get state-of-the-art urologicincorporating stereotactic radiation for kidneythe innate immune response. (Chen and Chen, ablation of kidney tumors. (Trimmer et al., JDrs. Carroll, Benjamin Chen, Mason, Wan, andHammers, Hao, Hsieh, Wan, and Wang. care. cancer tumor thrombi prior to surgery, led byNature, 2018) Vasc Interv Radiol, 2015) Zhang. Drs. Kapur and Brugarolas report the devel- The Health System Office of QualityDrs. Hannan and Margulis.Dr. Cadeddu receives the 2018 Patricia and Medical oncologist Dr. Lohrey is recruited toDrs. Kapur and Brugarolas validate HIF-2 as aopment of mouse models of the two mostImprovement performs a study of kidneyDr. DeBerardinis is appointed Investigator of theWilliam L. Watson Award for Excellence in Clinical UT Southwestern as Medical Director of thetarget in ccRCC. (Chen et al., Nature, 2016) common types of kidney cancer, and showcancer patient outcomes, showing improvedHoward Hughes Medical Institute.Medicine.that BAP1 and PBRM1 control kidney cancersurvival rates across stages, including ratesDrs. Chintalapati and Cai and medical student Harold C. Simmons Comprehensive CancerDr. Cadeddu reports that histologic subtypeaggressiveness. (Gu et al., Cancer Discov,that are double national benchmarks for stageDr. Banaszynski is a funding recipient of the firstJonathan Schoenhals receive prizes at the Center at the Moncrief Cancer Institute in Fortinfluences results of percutaneous radiofre- 2017) 4 patients. national Kidney Cancer Research Program.Second Annual Kidney Cancer Program retreat.Worth. quency ablation. (Lay et al., J Urol, 2016) Dr. Madhuranthakam is awarded a prestigiousUT Southwestern is ranked worlds No. 1 aca-Drs. Hannan, Brugarolas, and TimmermanIn collaboration with Mayo Clinic,National Institutes of Health U01 grant focusing2018 demic medical center for published research in2019publish the first report of SBRT (stereotacticDrs. Kapur and Brugarolas report that ccRCCon developing a radiology test to monitor treat- Dr. Courtney reports the results of a phase 1the healthcare area by Nature Index. Drs. Bowman, Wardak, Brugarolas and body radiation therapy) for tumor thrombi.can be divided into four subtypes according toment response in renal and other cancers.clinical trial of a first-in-class HIF-2 inhibitorUT Southwestern is recognized by the VHLTimmerman report on the treatment of patients (Hannan et al., Cancer Biol Ther, 2015) BAP1 and PBRM1 status with marked differ- Dr. Zhijian James Chen reports a novel(PT2385) developed by Peloton Therapeutics,Alliance as a VHL Clinical Care Center.with brain metastases, with outcomes approach-UT Southwestern and Texas Healthences in patient survival. (Joseph et al., STING-activating nanovaccine to boost anti-Inc. in the UT Southwestern BioCenter, showinging those of patients without brain metastases. Resources commit to integrating operationsJ Urol, 2016) tumor immunity in cancer immunotherapy. (Luoexcellent tolerability and activity in extensivelyDr. Zhijian James Chen reports on the mech- (Bowman et al., Clin Genitourin Cancer, 2019; to provide affordable, high-quality care forPatients Tony Towler and Merlinda Cheletteet al., Nat Nanotechnol, 2017) pretreated patients. (Courtney et al., J Clinanism by which droplet-size microreactors formWardak et al., Clin Genitourin Cancer, 2019) kidney cancer and other patients. initiate advocacy program. Oncol, 2018) when cGAS, a critical sensor that activates Dr. Cadeddu serves as a panel member of theWith support from the Kidney Cancer Coalition,innate immunity, encounters pathogenic DNA.Dr. Koh is the inaugural recipient of the KCP/Dr. Zhijian James Chen reports on a shared2017 American Urological Association ManagementPatient Advocates Merlinda Chelette and Brenda(Du and Chen, Science, 2018) SPORE yearlong grant funding opportunity for his signaling mechanism employed by the innateof Small Renal Mass Guidelines. Stinson organize the second Dallas CountryUT Southwestern is selected as one of fourproposal to study the role of the microbiome in immune system. (Liu et al., Science, 2015) Dr. Bowman joins the faculty in MedicalWith funds raised through Joeys Wings, KathyClub fundraising event, raising $100,000.institutions to receive a national Consortiumthe response to immunotherapy. Oncology, after finishing his fellowship in 2016 Hematology/Oncology and serving as chiefLiu provides $100,000 to support research onDr. Hannan reports the UT Southwestern experi- Development Award from the CongressionallyThe Health System Office of Quality Dr. Hammers, an immunotherapy thoughtfellow at UT Southwestern. translocation carcinomas. The award leadsence combining immune checkpoint inhibitors anddirected Kidney Cancer Research Program. Improvement releases an updated report of leader, joins the Kidney Cancer Program fromto the development of a mouse model andSBRT. (Mohamad et al., Oncoimmunology, 2018) outcomes of kidney cancer patients compared 74 75'